Publications

1. Hansen DK, Gautam S, Lafeuille MH, Rossi C, Moore B, Tardif-Samson A, Thompson-Leduc P, Fu AZ, Cortoos A, Kaila S, Fonseca R. Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma. Cancer Med. 2024 Nov; 13 (21):e70308
   View PubMed
2. Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Moran-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Sireesha Asoori Asoori, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen DK. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024 Oct 16; 14 (1):180
   View PubMed
3. Tang H, Yan H, Shivaram S, Lehman S, Sharma N, Smadbeck J, Zepeda-Mendoza C, Tian S, Asmann Y, Vachon C, Gaspar Maia A, Keats J, Bergsagel PL, Fonseca R, Stewart AK, Hsu JS, Kandasamy RK, Pandey A, Kaddoura MA, Maura F, Mitra A, Rajkumar SV, Kumar SK, Elhaik E, Braggio E, Baughn LB. Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14). Leukemia. 2024 Oct 14 [Epub ahead of print]
   View PubMed
4. Mian H, Kaiser M, Fonseca R. Still high risk? A review of translocation t(14;16) in multiple myeloma. Am J Hematol. 2024 Oct; 99 (10):1979-1987 Epub 2024 June 14
   View PubMed
5. Shim KG, Fonseca R. Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies. Cancers (Basel). 2024 Sep 27; 16 (19) Epub 2024 Sept 27
   View PubMed
6. Visram A, Chan KK, Seow H, Pond G, Gayowsky A, Mohyuddin GR, McCurdy A, Sandhu I, Venner C, Lancman G, Balitsky A, Kouroukis T, Bruins R, Kumar S, Fonseca R, Mian H. Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study. Haematologica. 2024 Aug 22 [Epub ahead of print]
   View PubMed
7. Wonnaparhown A, Hilal T, Squire J, Freeman C, Fonseca R. IgG replacement in multiple myeloma. Blood Cancer J. 2024 Jul 25; 14 (1):124 Epub 2024 July 25
   View PubMed
8. Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, Kumar S, Sarosiek S, Paludo J, Chhabra S, Cook JM, Parrondo R, Dispenzieri A, Gonsalves WI, Muchtar E, Ailawadhi S, Kyle RA, Rajkumar SV, Delmer A, Fonseca R, Gertz MA, Treon SP, Ansell SM, Castillo JJ, Kapoor P. Simplified Risk Stratification Model for Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42 (21):2527-2536 Epub 2024 May 24
   View PubMed
9. Ferreira Felix I, Collini M, Fonseca R, Guida C, Armaganijan L, Healey JS, Carvalho G. Conduction system pacing versus biventricular pacing in heart failure with reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2024 Jun; 21 (6):881-889 Epub 2024 Feb 19
   View PubMed
10. Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O'Donnell E, Prosper F, Shah UA, Sklavenitis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discov. 2024 May 1; 5 (3):146-152
    View PubMed
11. Pereyra Pietri M, Farina JM, Mahmoud AK, Scalia IG, Galasso F, Killian ME, Suppah M, Kenyon CR, Koepke LM, Padang R, Chao CJ, Sweeney JP, Fortuin FD, Eleid MF, Sell-Dottin KA, Steidley DE, Scott LR, Fonseca R, Lopez-Jimenez F, Attia ZI, Dispenzieri A, Grogan M, Rosenthal JL, Arsanjani R, Ayoub C. The prognostic value of artificial intelligence to predict cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J Digit Health. 2024 May; 5 (3):295-302 Epub 2024 Mar 13
    View PubMed
12. Derman BA, Fonseca R. Measurable Residual Disease and Decision-Making in Multiple Myeloma. Hematol Oncol Clin North Am. 2024 Apr; 38 (2):477-495 Epub 2024 Jan 06
    View PubMed
13. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J. 2024 Jan 25; 14 (1):20
    View PubMed
14. Gagnon MF, Midthun SM, Fangel JA, Schuh CM, Luoma IM, Pearce KE, Meyer RG, Ailawadhi S, Arribas MJ, Braggio E, Fonseca R, Rajkumar SV, Zepeda-Mendoza C, Xu X, Greipp PT, Timm MM, Otteson GE, Shi M, Jevremovic D, Olteanu H, Peterson JF, Ketterling RP, Kumar S, Baughn LB. Superior detection rate of plasma cell FISH using FACS-FISH. Am J Clin Pathol. 2024 Jan 4; 161 (1):60-70
    View PubMed
15. Alhaj Moustafa M, Parrondo R, Abdulazeez MF, Roy V, Sher T, Alegria VR, Warsame RM, Fonseca R, Rasheed A, Gonsalves WI, Kourelis T, Kapoor P, Buadi FK, Dingli D, Hayman SR, Reeder CB, Chanan-Khan AA, Ailawadhi S. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. Anticancer Drugs. 2024 Jan 1; 35 (1):63-69 Epub 2023 Apr 06
    View PubMed
16. Fonseca R, Rossi A, Medhekar R, Voelker J, Homan T, Wilcock J, Karakusevic A, Cochrane J, Bridge D, Perry R, Kaila S, Davies FE. Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel. Future Oncol. 2024; 20 (23):1645-1656 Epub 2024 May 20
    View PubMed
17. McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, D'Souza A, Mohyuddin GR, Wildes TM, Fonseca R, Mian H. Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 2023 Dec 1; 108 (12):3384-3391 Epub 2023 Dec 01
    View PubMed
18. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878
    View PubMed
19. Fonseca R, Chinaeke EE, Gupta-Werner N, Fu AZ, Kaila S. Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States. Mayo Clin Proc Innov Qual Outcomes. 2023 Oct; 7 (5):430-436 Epub 2023 Sept 15
    View PubMed
20. Kumar S, Dispenzieri A, Bhutani D, Gertz M, Wechalekar A, Palladini G, Comenzo R, Fonseca R, Jaccard A, Kastritis E, Schonland S, la Porte C, Pei H, Tran N, Merlini G. Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. Amyloid. 2023 Sep; 30 (3):268-278 Epub 2023 Feb 13
    View PubMed
21. Fonseca R, Tran D, Laidlaw A, Rosta E, Rai M, Duran J, Ammann EM. Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review. Clin Lymphoma Myeloma Leuk. 2023 Jun; 23 (6):426-437.e11 Epub 2023 Mar 18
    View PubMed
22. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jun; 23 (6):456-462 Epub 2023 Mar 07
    View PubMed
23. Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, Gonzalez Velez M, Kosiorek HE, Butterfield RDJ, Kirsch IR, Mikhael JR, Stewart AK, Reeder C, Larsen J, Bergsagel PL, Fonseca R. Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023 May 26; 13 (1):87
    View PubMed
24. Fonseca R, Facon T, Hashim M, Nair S, He J, Ammann E, Lam A, Wildgust M, Kumar S. Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma. Oncologist. 2023 May 8; 28 (5):e263-e269
    View PubMed
25. Bansal R, Baksh M, Larsen JT, Hathcock MA, Dingli D, Stewart AK, Kapoor P, Kourelis T, Hayman SR, Warsame RM, Fonseca R, Bergsagel PL, Ailawadhi S, Kumar SK, Lin Y. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J. 2023 Apr 5; 13 (1):47 Epub 2023 Apr 05
    View PubMed
26. Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, Gonzalez Velez M, Kosiorek HE, Butterfield RDJ, Kirsch IR, Mikhael JR, Stewart AK, Reeder C, Larsen J, Bergsagel PL, Fonseca R. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023 Mar 6; 13 (1):32 Epub 2023 Mar 06
    View PubMed
27. Gallardo-Perez MM, Gale RP, Reyes-Cisneros OA, Sanchez-Bonilla D, Fernandez-Gutierrez JA, Stock W, Murrieta-Alvarez I, Olivares-Gazca JC, Ruiz-Delgado GJ, Fonseca R, Ruiz-Arguelles GJ. Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces. Front Oncol. 2023; 13:1187268 Epub 2023 June 16
    View PubMed
28. Sweeney NW, Ahlstrom JM, Fonseca R, Davies FE, Thompson MA. Errata. JCO Clinical Cancer Informatics. 2023; 6:e2200053
    
29. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24
    View PubMed
30. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood. 2022 Nov 3; 140 (18):1997-2000
    View PubMed
31. Voleti SS, Warsame R, Mead-Harvey C, Ailawadhi S, Jain A, Fonseca R, Griffin JM, Khera N. Assessing Patient-Reported Financial Hardship in Patients With Cancer in Routine Clinical Care. JCO Oncol Pract. 2022 Nov; 18 (11):e1839-e1853 Epub 2022 Sept 27
    View PubMed
32. Fonseca R, Wiedmeier JE, Arribas M, Fonseca R. MM-361 The Prognostic Role and Utility of Highly Sensitive Minimal Residual Disease Assay in Multiple Myeloma: Is There Really a Difference? Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S420
    View PubMed
33. Evans LA, Anderson EA, Jessen E, Nandakumar B, Atilgan E, Jevremovic D, Hitosugi T, Fonseca R, Kumar SK, Gonsalves WI. Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma. Am J Hematol. 2022 Jul; 97 (7):895-902 Epub 2022 May 06
    View PubMed
34. El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, Ghobrial IM. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022 May; 9 (5):e340-e349 Epub 2022 Mar 25
    View PubMed
35. Sweeney NW, Ahlstrom JM, Davies FE, Fonseca R, Thompson MA. HealthTree Cure Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles and Accelerate Research in Multiple Myeloma. JCO Clin Cancer Inform. 2022 Feb; 6:e2100141
    View PubMed
36. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022 Jan 31; 12 (1):21
    View PubMed
37. Bal S, Kumar SK, Fonseca R, Gay F, Hungria VT, Dogan A, Costa LJ. Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res. 2022; 12 (7):2950-2965 Epub 2022 July 15
    View PubMed
38. Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves WI, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, Lin Y, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021 Jun; 96(6):1546-1577.
    View PubMed
39. Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021 Apr 29; 11 (4):83
    View PubMed
40. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, Joao C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Blade J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 Mar; 22 (3):e105-e118
    View PubMed
41. Fonseca R, Hagiwara M, Panjabi S, Yucel E, Buchanan J, Delea T. Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. Blood Cancer J. 2021 Feb 16; 11 (2):35
    View PubMed
42. Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, Liedtke M, Jaccard A, Wechalekar AD, Comenzo R, Sanchorawala V, Royer B, Rosenzweig M, Valent J, Schonland S, Fonseca R, Wong S, Kapoor P. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021 Jan 11; 11 (1):10
    View PubMed
43. Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, Lam A, Ukropec J, Maiese EM, Nair S, Potluri R, Voorhees PM. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020 Nov 10; 20 (1):1087
    View PubMed
44. Mountjoy L, Sebastian S, Jain T, Hilal T, Gonzalez-Velez M, Girardo M, Ahmann G, Larsen J, Bergsagel L, Fonseca R. Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity. Leukemia 2020 Nov; 34 (11):3060-3063 Epub 2020 June 05
    View PubMed
45. Baughn LB, Sharma N, Elhaik E, Sekulic A, Bryce AH, Fonseca R. Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clin Proc. 2020 Sep; 95 (9):1989-1999 Epub 2020 July 19
    View PubMed
46. Bonolo de Campos C, Meurice N, Petit JL, Polito AN, Zhu YX, Wang P, Bruins LA, Wang X, Lopez Armenta ID, Darvish SA, Ahmann GJ, Henderson KJ, Tian S, Kruse JJ, Stewart WM, Larsen JT, Reeder CB, Dingli D, Kapoor P, Kumar SK, Fonseca R, Bergsagel PL, Braggio E, Stewart AK. "Direct to Drug" screening as a precision medicine tool in multiple myeloma. Blood Cancer J. 2020 May 11; 10 (5):54
    View PubMed
47. Sidiqi MH, Al Saleh AS, Leung N, Jevremovic D, Aljama MA, Gonsalves WI, Buadi FK, Kourelis TV, Warsame R, Muchtar E, Hobbs MA, Lacy MQ, Dingli D, Go RS, Hayman SR, Rajkumar SV, Dispenzieri A, Gertz MA, Kumar SK, Fonseca R, Kapoor P. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J 2020 May 11; 10 (5):55
    View PubMed
48. Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, Agius MP, Park J, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Liu CJ, He MX, Braggio E, Fonseca R, Maruvka YE, Guerriero JL, Goldman M, Van Allen EM, McCarroll SA, Azzi J, Getz G, Ghobrial IM. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020 May; 1 (5):493-506 Epub 2020 Apr 27
    View PubMed
49. Cinar P, Kubal T, Freifeld A, Mishra A, Shulman L, Bachman J, Fonseca R, Uronis H, Klemanski D, Slusser K, Lunning M, Liu C. Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. J Natl Compr Canc Netw. 2020 Apr 15; 1-6 [Epub ahead of print]
    View PubMed
50. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020 Apr 10; 38 (11):1126-1137 Epub 2019 Oct 25
    View PubMed
51. Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. Value Health. 2020 Apr; 23 (4):441-450 Epub 2020 Apr 06
    View PubMed
52. Fonseca R, Beura LK, Quarnstrom CF, Ghoneim HE, Fan Y, Zebley CC, Scott MC, Fares-Frederickson NJ, Wijeyesinghe S, Thompson EA, Borges da Silva H, Vezys V, Youngblood B, Masopust D. Developmental plasticity allows outside-in immune responses by resident memory T cells. Nat Immunol. 2020 Apr; 21 (4):412-421 Epub 2020 Feb 17
    View PubMed
53. Fonseca R, Gonzalez-Velez M. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-7
    View PubMed
54. Wolf J, Fonseca R, Muffly L. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph. Clin Adv Hematol Oncol. 2020 Mar; 18 Suppl 9 (3):1-16
    View PubMed
55. Fonseca R. Assessment of MRD in patients with hematologic malignancies: clinical insights. Clin Adv Hematol Oncol. 2020 Mar; 18 Suppl 9 (3):7-10
    View PubMed
56. Hagiwara M, Panjabi S, Delea T, Yucel E, Fonseca R. Burden of disease progression in patients with multiple myeloma in the US. Leuk Lymphoma. 2020 Jan; 61 (1):47-55 Epub 2019 Aug 07
    View PubMed
57. Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortum KM, Keats JJ, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL, MMRF CoMMpass Network. MYC dysregulation in the progression of multiple myeloma. Leukemia 2020 Jan; 34 (1):322-326 Epub 2019 Aug 22
    View PubMed
58. Jethava YS, Fonseca R, Landgren O. Management of multiple myeloma during COVID-19 pandemic. Leuk Res Rep. 2020; 14:100212 Epub 2020 June 13
    View PubMed
59. LeBlanc TW, Baile WF, Eggly S, Bylund CL, Kurtin S, Khurana M, Najdi R, Blaedel J, Wolf JL, Fonseca R. Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. Patient Educ Couns. 2019 Sep; 102 (9):1602-1612 Epub 2019 Apr 26
    View PubMed
60. Ailawadhi S, Sher T, Azzouqa AG, Meghji Z, Jain T, Jani P, Ahmed S, Diehl N, Roy V, Shah V, Hodge D, Ailawadhi M, Alegria VR, Paulus A, Chanan-Khan A, Fonseca R. Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anticancer Drugs. 2019 Sep; 30 (8):859-865
    View PubMed
61. Strouse C, Briasoulis A, Fonseca R, Jethava Y. Approach to a patient with cardiac amyloidosis. J Geriatr Cardiol. 2019 Jul; 16 (7):567-574
    View PubMed
62. Sahin I, Kawano Y, Sklavenitis-Pistofidis R, Moschetta M, Mishima Y, Manier S, Sacco A, Carrasco R, Fonseca R, Roccaro AM, Witzig T, Ghobrial IM. Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019 Apr 9; 3 (7):995-1002
    View PubMed
63. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar; 54 (3):353-367 Epub 2018 July 09
    View PubMed
64. Kim C, Bhatta S, Cyprien L, Fonseca R, Hernandez RK. Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data. J Bone Oncol. 2019 Feb; 14:100215 Epub 2018 Dec 26
    View PubMed
65. Jain T, Sonbol MB, Firwana B, Kolla KR, Almader-Douglas D, Palmer J, Fonseca R. High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 Feb; 25 (2):239-247 Epub 2018 Sept 20
    View PubMed
66. Huskey JL, Heilman RL, Khamash H, Fonseca R. Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma. Transplantation. 2018 Dec; 102 (12):1994-2001
    View PubMed
67. Fonseca R, Peneva D, Clancy Z, Abouzaid S, Jena AB. The Importance of Economic Trade-offs in Cancer Drug Pricing. Mayo Clin Proc. 2018 Aug; 93 (8):976-979 Epub 2018 June 23
    View PubMed
68. Gonzalez-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018 Aug; 97 (8):1453-1462 Epub 2018 Apr 06
    View PubMed
69. Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018 Jul 30; 8 (8):70 Epub 2018 July 30
    View PubMed
70. Jain T, Kosiorek HE, Kung ST, Shah VS, Dueck AC, Gonzalez-Calle V, Luft S, Reeder CB, Adams R, Noel P, Larsen JT, Mikhael J, Bergsagel L, Stewart AK, Fonseca R. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2018 Jul; 18 (7):486-492.e1 Epub 2018 May 04
    View PubMed
71. Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA, Block KE, Fonseca R, Yan Y, Hippen KL, Blazar BR, Masopust D, Kelekar A, Vulchanova L, Hogquist KA, Jameson SC. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8(+) T cells. Nature. 2018 Jul; 559 (7713):264-268 Epub 2018 July 04
    View PubMed
72. Fonseca R, Hinkel J. Value and Cost of Myeloma Therapy-We Can Afford It. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:647-655
    View PubMed
73. Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 Mar 20; 36 (9):859-866 Epub 2018 Jan 30
    View PubMed
74. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01
    View PubMed
75. Fonseca R, Salgado RM, Borges da Silva H, do Nascimento RS, D'Imperio-Lima MR, Alvarez JM. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic Trypanosoma cruzi Infection. Front Immunol. 2018; 9:997 Epub 2018 May 07
    View PubMed
76. Gonzalez-Calle V, Keane N, Braggio E, Fonseca R. Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clin Lymphoma Myeloma Leuk. 2017 Oct; 17 (10):621-630 Epub 2017 June 23
    View PubMed
77. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06
    View PubMed
78. Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017 Sep; 31 (9):1915-1921 Epub 2016 Dec 23
    View PubMed
79. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265
    View PubMed
80. van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 Sep; 17 (9):555-562 Epub 2017 July 04
    View PubMed
81. Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD. Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. Clin Genitourin Cancer. 2017 Aug; 15 (4):e727-e734 Epub 2016 Dec 01
    View PubMed
82. Fonseca R, Cesarman-Maus G, Braggio E. Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer. J Clin Oncol 2017 Jul 1; 35 (19):2217-2218 Epub 2017 May 08
    View PubMed
83. Fonseca R. Use of genetic markers in multiple myeloma. Clin Adv Hematol Oncol. 2017 Jun; 15 (6):446-448
    View PubMed
84. Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Stewart AK, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. Am J Hematol. 2017 May; 92 (5):467-472 Epub 2017 Mar 22
    View PubMed
85. Panchabhai S, Schlam I, Sebastian S, Fonseca R. PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma. Leukemia. 2017 Apr; 31 (4):991-994 Epub 2016 Dec 27
    View PubMed
86. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11
    View PubMed
87. Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R. Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. Blood. 2017 Feb 23; 129 (8):991-1007 Epub 2016 Dec 27
    View PubMed
88. Nasr SH, Dasari S, Mills JR, Theis JD, Zimmermann MT, Fonseca R, Vrana JA, Lester SJ, McLaughlin BM, Gillespie R, Highsmith WE Jr, Lee JJ, Dispenzieri A, Kurtin PJ. Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. J Am Soc Nephrol. 2017 Feb; 28 (2):431-438 Epub 2017 Jan 03
    View PubMed
89. Colon-Otero G, Van Wier SA, Ahmann GJ, Braggio E, Albertie ML, Weis JA, Ailawadhi S, Cerhan JR, Vishnu P, Jorgensen MS, Foran JM, Thomas CS, Fonseca R. Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. Ann Hematol. 2017 Jan; 96 (1):51-55 Epub 2016 Oct 12
    View PubMed
90. Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortum KM, Pathangey S, Van-Dyke DL, Slager SL, Fonseca R, Kay NE, Braggio E. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia. 2017 Jan; 31 (1):170-176 Epub 2016 June 14
    View PubMed
91. Gonzalez-Calle V, Fonseca R. [Towards precision medicine in myeloma: new evidence and challenges]. Medicina (B Aires). 2017; 77 (3):222-226
    View PubMed
92. Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH. Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Sci Rep. 2016 Dec 23; 6 (1):25
    View PubMed
93. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016 Dec; 22 (12):1411-1420 Epub 2016 Nov 14
    View PubMed
94. Teoh PJ, Bi C, Sintosebastian C, Tay LS, Fonseca R, Chng WJ. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget. 2016 Sep 20; 7 (38):61806-61819
    View PubMed
95. Biran N, Jacobus S, Vesole DH, Callander NS, Fonseca R, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR, Siegel DS. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer J. 2016 Sep 2; 6 (9):e466 Epub 2016 Sept 02
    View PubMed
96. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1; 128 (9):1174-80 Epub 2016 July 20
    View PubMed
97. Jacobus SJ, Rajkumar SV, Weiss M, Stewart AK, Stadtmauer EA, Callander NS, Dreosti LM, Lacy MQ, Fonseca R. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J 2016 Jul 29; 6 (7):e448 Epub 2016 July 29
    View PubMed
98. Qaqish I, Schlam IM, Chakkera HA, Fonseca R, Adamski J. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apher Sci. 2016 Jun; 54: (3)401-4.
    View PubMed
99. Coakley M, Yeneneh B, Rosenthal A, Fonseca R, Mookadam F. Extramedullary Cardiac Multiple Myeloma-A Case Report and Contemporary Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 May; 16: (5)246-52.
    View PubMed
100. Panchabhai S, Kelemen K, Ahmann G, Sebastian S, Mantei J, Fonseca R. Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia 2016 Apr; 30 (4):951-4 Epub 2015 July 23
     View PubMed
101. Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J. 2016 Feb 26; 6:e397
     View PubMed
102. Rosenthal A, Luthi J, Belohlavek M, Kortum KM, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart AK. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016 Jan 15; 6 (1):e384
     View PubMed
103. Azadeh N, Tazelaar HD, Gotway MB, Mookadam F, Fonseca R. Erdheim Chester Disease treated successfully with cladribine. Respir Med Case Rep. 2016; 18:37-40 Epub 2016 Apr 04
     View PubMed
104. Segarra VA, DeLucia AA, DeLucia AA, Fonseca R, Penfold MP, Sawyer KM, Harold CM, Reddig C, Singh A, Musri I, Wright JC, Leissing JJ, Dennis S, Pflug MC, Fogle N, Moore M, Sims S, Matteson K, Hein M. Self-Driven Service Learning: Community-Student-Faculty Collaboratives Outside of the Classroom. J Microbiol Biol Educ. 2015 Dec; 16 (2):260-2 Epub 2015 Dec 01
     View PubMed
105. Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015 Sep 22; 6 (28):26508-18
     View PubMed
106. Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 2015 Sep 10; 126 (11):1294-301 Epub 2015 July 08
     View PubMed
107. Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA, Valdez R, Tibes R, Eckloff B, Witzig TE, Stewart AK, Fonseca R, O'Neill BP. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clin Cancer Res. 2015 Sep 1; 21 (17):3986-94 Epub 2015 May 19
     View PubMed
108. Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14; 5:e338
     View PubMed
109. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
     View PubMed
110. Kortum KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol. 2015 Jul; 94 (7):1205-11 Epub 2015 Mar 07
     View PubMed
111. Ojha J, Secreto CR, Rabe KG, Van Dyke DL, Kortum KM, Slager SL, Shanafelt TD, Fonseca R, Kay NE, Braggio E. Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br J Haematol 2015 May; 169 (3):445-8 Epub 2014 Nov 10
     View PubMed
112. Kortum KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. Br J Haematol. 2015 Feb; 168 (4):507-10 Epub 2014 Oct 10
     View PubMed
113. Borges da Silva H, Fonseca R, Cassado A, Machado de Salles E, de Menezes MN, Langhorne J, Perez KR, Cuccovia IM, Ryffel B, Barreto VM, Marinho CR, Boscardin SB, Alvarez JM, D'Imperio-Lima MR, Tadokoro CE. In vivo approaches reveal a key role for DCs in CD4+ T cell activation and parasite clearance during the acute phase of experimental blood-stage malaria. PLoS Pathog. 2015 Feb; 11 (2):e1004598 Epub 2015 Feb 06
     View PubMed
114. Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK, Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15; 125 (3):443-8 Epub 2014 Nov 13
     View PubMed
115. Ojha J, Ayres J, Secreto C, Tschumper R, Rabe K, Van Dyke D, Slager S, Shanafelt T, Fonseca R, Kay NE, Braggio E. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood. 2015 Jan 15; 125 (3):492-8 Epub 2014 Nov 06
     View PubMed
116. Borges da Silva H, Fonseca R, Pereira RM, Cassado A, Alvarez JM, D'Imperio Lima MR. Splenic Macrophage Subsets and Their Function during Blood-Borne Infections. Front Immunol. 2015; 6:480 Epub 2015 Sept 22
     View PubMed
117. Borges da Silva H, Fonseca R, Alvarez JM, D'Imperio Lima MR. IFN-gamma Priming Effects on the Maintenance of Effector Memory CD4(+) T Cells and on Phagocyte Function: Evidences from Infectious Diseases. J Immunol Res. 2015; 2015:202816 Epub 2015 Oct 05
     View PubMed
118. Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, Slager S, Fonseca R, Shanafelt T, Kay N, Braggio E. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia 2014 Dec; 28 (12):2395-8 Epub 2014 July 18
     View PubMed
119. Azadeh N, Kelemen K, Fonseca R. Amitriptyline-induced agranulocytosis with bone marrow confirmation. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):e183-5. Epub 2014 Jun 11.
     View PubMed
120. Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, Fonseca R, Chng WJ. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia. 2014 Oct; 28 (10):2066-74 Epub 2014 Mar 14
     View PubMed
121. Gordon GW, Monge J, Channon MB, Wu Q, Skulan JL, Anbar AD, Fonseca R. Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition. Leukemia 2014 Oct; 28 (10):2112-5 Epub 2014 June 12
     View PubMed
122. Affer M, Chesi M, Chen WG, Keats JJ, Demchenko YN, Roschke AV, Van Wier S, Fonseca R, Bergsagel PL, Kuehl WM. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014 Aug; 28 (8):1725-1735 Epub 2014 Feb 12
     View PubMed
123. Kortuem KM, Zidich K, Schuster SR, Khan ML, Jimenez-Zepeda VH, Mikhael JR, Fonseca R, Stewart AK. Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14 (4):284-290.e5 Epub 2013 Dec 28
     View PubMed
124. Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014 Jul 24; 124 (4):536-45 Epub 2014 June 09
     View PubMed
125. Patrick O'Neill B, Braggio E, O'Neill BP, Van Wier S, Ojha J, McPhail E, Asmann Y, Egan J, Ayres da Silva J, Schiff D, Lopes MB, Valdez R, Tibes R, Eckloff B, Stewart AK, Fonseca R. Genome-wide analysis uncovers recurrent alterations in primary central nervous system lymphomas (pcnsl). Neuro Oncol. 2014 Jul; 16 Suppl 3:iii43.
     View PubMed
126. Cesarman-Maus G, Braggio E, Lome-Maldonado C, Morales-Leyte AL, Fonseca R. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res. 2014 Apr; 133 (4):606-9 Epub 2014 Jan 23
     View PubMed
127. Mereuta OM, Theis JD, Vrana JA, Law ME, Grogg KL, Dasari S, Chandan VS, Wu TT, Jimenez-Zepeda VH, Fonseca R, Dispenzieri A, Kurtin PJ, Dogan A. Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood. 2014 Mar 6; 123 (10):1479-82 Epub 2014 Jan 10
     View PubMed
128. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert-Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Stewart K, Then GC, Wieben ED, Farrugia G. Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):15-23. Epub 2014 Mar 10.
     View PubMed
129. Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T, Ziesmer S, Li Y, Johnson SH, Hart SN, Kocher JP, Vasmatzis G, Chanan-Kahn A, Gertz M, Fonseca R, Dogan A, Cerhan JR, Novak AJ. Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer J. 2014 Feb 14; 4:e183
     View PubMed
130. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014 Feb; 10 (2):e1004135 Epub 2014 Feb 13
     View PubMed
131. Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Rev Hematol. 2014 Feb; 7 (1):21-31
     View PubMed
132. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb; 28 (2):269-77 Epub 2013 Aug 26
     View PubMed
133. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014 Jan; 38 (1):23-8 Epub 2013 Sept 05
     View PubMed
134. Egan JB, Barrett MT, Champion MD, Middha S, Lenkiewicz E, Evers L, Francis P, Schmidt J, Shi CX, Van Wier S, Badar S, Ahmann G, Kortuem KM, Boczek NJ, Fonseca R, Craig DW, Carpten JD, Borad MJ, Stewart AK. Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements. PLoS One. 2014; 9 (2):e87113 Epub 2014 Feb 05
     View PubMed
135. Alvarez JM, Fonseca R, Borges da Silva H, Marinho CR, Bortoluci KR, Sardinha LR, Epiphanio S, D'Imperio Lima MR. Chagas disease: still many unsolved issues. Mediators Inflamm. 2014; 2014:912965 Epub 2014 June 29
     View PubMed
136. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122 (26):4172-81 Epub 2013 Oct 21
     View PubMed
137. Jimenez-Zepeda VH, Braggio E, Fonseca R. Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):552-8. Epub 2013 Jul 12.
     View PubMed
138. Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, Fonseca R. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. 2013 Oct; 98(10):1586-92. Epub 2013 May 28.
     View PubMed
139. Fonseca R, Monge J. Myeloma: classification and risk assessment. Semin Oncol. 2013 Oct; 40(5):554-66.
     View PubMed
140. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013 Aug; 27 (8):1738-44 Epub 2013 Mar 21
     View PubMed
141. Jimenez-Zepeda VH, Chng WJ, Schop RF, Braggio E, Leis JF, Kay N, Fonseca R. Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):467-76.
     View PubMed
142. Braggio E, Egan JB, Fonseca R, Stewart AK. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J. 2013 Jul 19; 3:e127 Epub 2013 July 19
     View PubMed
143. Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, Jelinek DF, Carpten J, Fonseca R. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013 Apr 18; 121(16):3147-52. Epub 2013 Feb 19.
     View PubMed
144. Rio-Machin A, Ferreira BI, Henry T, Gómez-López G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martínez J, Fonseca R, Cigudosa JC. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia. 2013 Apr; 27(4):925-31. Epub 2012 Oct 22.
     View PubMed
145. Braggio E, Fonseca R. Genomic abnormalities of Waldenstrom macroglobulinemia and related low-grade B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13 (2):198-201 Epub 2013 Mar 09
     View PubMed
146. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Blade J, Orlowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr; 27(4):780-91. Epub 2012 Nov 21
     View PubMed
147. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88 (4):360-76
     View PubMed
148. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G, International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013 Mar; 27(3):711-7. Epub 2012 Oct 03.
     View PubMed
149. Braggio E, Fonseca R, Kay NE. CGH protocols: chronic lymphocytic leukemia. Methods Mol Biol. 2013; 973:87-98.
     View PubMed
150. Chung TH, Mulligan G, Fonseca R, Chng WJ. A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS One. 2013; 8(6):e66361. Epub 2013 Jun 20.
     View PubMed
151. Delgado M, Legeren M, Jurado JM, Zarcos I, Sanchez MJ, Fonseca R, Villaescusa A, Galvez F, Calvo A, Garcia-Puche JL. Advanced medullary thyroid cancer treated with Sorafenib: A case report. Journal of Solid Tumors. 2013; 3(1):34-37.
     
152. Ansell SM, Akasaka T, McPhail E, Manske M, Braggio E, Price-Troska T, Ziesmer S, Secreto F, Fonseca R, Gupta M, Law M, Witzig TE, Dyer MJ, Dogan A, Cerhan JR, Novak AJ. t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood. 2012 Nov 8; 120 (19):3949-57 Epub 2012 Sept 10
     View PubMed
153. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, Thompson EA, Kadin ME, Milosevic D, Porcher JC, Asmann YW, Smith DI, Kovtun IV, Ansell SM, Dogan A, Feldman AL. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012 Sep 13; 120 (11):2280-9 Epub 2012 Aug 01
     View PubMed
154. Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica. 2012 Sep; 97 (9):1281-90 Epub 2012 July 06
     View PubMed
155. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012 Aug 2; 120 (5):1060-6 Epub 2012 Apr 23
     View PubMed
156. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012 Aug 2; 120 (5):1067-76 Epub 2012 Apr 12
     View PubMed
157. Cesarman-Maus G, Braggio E, Maldonado H, Fonseca R. Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia. 2012 Jul; 26(7):1671-4. Epub 2012 Feb 15.
     View PubMed
158. Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 2012 Jul; 26 (7):1698-701 Epub 2012 Jan 20
     View PubMed
159. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7; 119 (23):5397-404 Epub 2012 Apr 04
     View PubMed
160. Wagner LI, Robinson D, Weiss M, Katz M, Greipp P, Fonseca R, Cella D. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage. 2012 Jun; 43(6):1094-104. Epub 2012 May 09.
     View PubMed
161. Colon-Otero G, Albertie M, Lesperance M, Weis JA, Coles A, Smith N, Mills L, Woodward T, Aspitia AM, Vishnu P, Willis F, Isley A, Fonseca R, Vachon C, Rajkumar SV. A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans. J Cancer Educ. 2012 Jun; 27 (2):294-8
     View PubMed
162. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24; 119 (21):4860-7 Epub 2012 Apr 13
     View PubMed
163. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10; 119 (19):4391-4 Epub 2012 Feb 13
     View PubMed
164. Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol. 2012 May; 25 (5):651-60 Epub 2012 Feb 03
     View PubMed
165. Fonseca R. Frontline treatment of multiple myeloma. Hematology. 2012 Apr; 17 Suppl 1:S101-4
     View PubMed
166. Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology. 2012 Apr; 17 Suppl 1:S177-80.
     View PubMed
167. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012 Mar 1; 119 (9):2100-5 Epub 2012 Jan 10
     View PubMed
168. Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol. 2012 Feb; 156 (3):326-33 Epub 2011 Nov 23
     View PubMed
169. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7 (10):e43192 Epub 2012 Oct 10
     View PubMed
170. Jung S, Kim S, Gale M, Cherni I, Fonseca R, Carpten J, Salhia B. DNA methylation in multiple myeloma is weakly associated with gene transcription. PLoS ONE. 2012; 7(12):e52626.
     View PubMed
171. Weber MA, Black HR, Fonseca R, Garber J, Gonzalez-Campoy JM, Kimmelstiel C, Markowitz AB, Nakayama D, Stell LK, Stossel TP. Association of clinical researchers and educators a statement on relationships between physicians and industry. Endocr Pract. 2012; 18(6):1029-37.
     View PubMed
172. Watkins AJ, Hamoudi RA, Zeng N, Yan Q, Huang Y, Liu H, Zhang J, Braggio E, Fonseca R, de Leval, Isaacson PG, Wotherspoon A, McPhail ED, Dogan A, Du MQ. An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLoS One. 2012; 7(9):e44997. Epub 2012 Sep 13.
     View PubMed
173. Pashos CL, Durie BGM, Rifkin R, Terebelo H, Gasparetto C, Mehta J, Toomey K, Abonour R, Fonseca R, Narang M, Shah JJ, Swem AS, Sullivan KA, Street TK, Khan ZM. Variation in health-related quality of life (HRQOL) among multiple myeloma patients by insurance coverage. Blood. 2011 Nov 18; 118(21):1361-2.
     
174. Braggio E, Kay N, Van Wier S, Tschumper RC, Smoley SA, Eckel-Passow JE, Sassoon T, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Blood. 2011 Nov 18; 118(21):1223-4.
     
175. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011 Nov 3; 118 (18):4771-9 Epub 2011 Aug 22
     View PubMed
176. Jacobus SJ, Kumar S, Uno H, Van Wier, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011 Nov; 155(3):340-8. Epub 2011 Sep 09.
     View PubMed
177. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20; 118 (16):4359-62 Epub 2011 Aug 22
     View PubMed
178. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15; 118 (11):2970-5 Epub 2011 June 20
     View PubMed
179. Jimenez-Zepeda VH, Heilman RL, Engel RA, Carey EJ, Freeman C, Rakela J, Mulligan DC, Fonseca R, Stewart AK. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation. 2011 Sep 15; 92 (5):570-4
     View PubMed
180. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011 Aug; 86 (8):640-5 Epub 2011 May 31
     View PubMed
181. Braggio E, McPhail ER, Macon W, Lopes MB, Schiff D, Law M, Fink S, Sprau D, Giannini C, Dogan A, Fonseca R, O'Neill BP. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res. 2011 Jul 1; 17 (13):4245-53 Epub 2011 May 11
     View PubMed
182. Hodge LS, Elsawa SF, Grote DM, Price-Troska TL, Asmann YW, Fonseca R, Gertz MA, Witzig TE, Novak AJ, Ansell SM. MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts. Blood Cancer J. 2011 Jun; 1(6):e24. Epub 2011 Jun 17.
     View PubMed
183. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011 Jun; 25 (6):1026-35 Epub 2011 Apr 05
     View PubMed
184. Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK, Price Troska TL, Ziesmer SC, Fonseca R, Witzig TE, Morice WG, Gertz MA, Ansell SM. Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. Blood. 2011 May 12; 117 (19):e190-7 Epub 2011 Mar 17
     View PubMed
185. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel, Crowley J, Avet-Loiseau H, International Myeloma. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 5; 117(18):4696-700. Epub 2011 Feb 03.
     View PubMed
186. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev. 2011 May; 25(3):107-12. Epub 2011 Feb 03.
     View PubMed
187. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
     View PubMed
188. Poulain S, Braggio E, Roumier C, Aijjou R, Broucqsault N, Galiegue-Zouitina S, Manier S, Soenen V, Nibourel O, Duthilleul P, Fonseca R, Leleu X. High-throughput genomic analysis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):106-8.
     View PubMed
189. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec; 203 (2):161-8
     View PubMed
190. Anderson KC, Cheson BD, Czuczman MS, Fonseca R, Gregory SA, Lonial S, Love N. Exploring the clinical decisions of US community-based oncologists and hematologists in the management of multiple myeloma and follicular lymphoma. Oncology. 2010 Dec; (Suppl 5):1-24.
     
191. Lonial S, Anderson KC, Fonseca R, Love N. Up-front management of multiple myeloma. Oncology-new York. 2010 Dec; 24(5):8-14.
     
192. Siegel DSD, Jacobus S, Rajkumar SV, Abonour R, Callander NS, Katz MS, Fonseca R, Vesole DH. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial. Blood. 2010 Nov 19; 116(21):22-3.
     
193. Ansell SM, Akasaka T, Manske M, Price-troska T, Ziesmer S, Braggio E, Fonseca R, Gupta M, Law ME, Witzig TE, Dyer MJS, Dogan A, Novak AJ. A newly identified translocation t(X;14)(p11;q32) In MALT lymphoma involving IGHS and GPR34 reveals a novel role for GPR34 in cell growth and tumor development. Blood. 2010 Nov 19; 116(21):833-4.
     
194. Dispenzieri A, Abraham M, Hayman SR, Buadi F, Kumar S, Reeder CB, Mikhael JR, Zeldenrust S, Rajkumar SV, Short KD, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Fonseca R, Bergsagel PL, Roy V, Stewart K, Lacy M. A phase-2 study of pomalidomide and dexamethasone in previously treated light chain (AL) amyloidosis. Blood. 2010 Nov 19; 116(21):434-5.
     
195. Braggio E, O'Neill BP, Macon W, Lopes MB, Schiff D, Fonseca R. Characterization of the Copy Number Changes In Primary CNS Lymphomas (PCNSL) by High Resolution Array Based Comparative Genomic Hybridization. Blood. 2010 Nov 19; 116(21):438-9.
     
196. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov; 24 (11):1934-9 Epub 2010 Sept 09
     View PubMed
197. Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res. 2010 Sep 1; 70(17):6934-44. Epub 2010 Aug 24.
     View PubMed
198. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85 (9):824-33 Epub 2010 Aug 11
     View PubMed
199. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep; 85 (9):664-9
     View PubMed
200. Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, Blood E, DeGoey R, Henderson K, Kyle RA, Bradwell AR, Greipp PR, Rajkumar SV, Fonseca R. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia. 2010 Aug; 24 (8):1498-505 Epub 2010 June 03
     View PubMed
201. Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia. 2010 Aug; 24 (8):1406-11 Epub 2010 June 10
     View PubMed
202. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul; 150(1):28-38. Epub 2010 May 09.
     View PubMed
203. Khan ML, Colby TV, Viggiano RW, Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):217-9.
     View PubMed
204. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc. 2010 Jun; 85 (6):532-7
     View PubMed
205. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010 May 15; 375 (9727):1721-8
     View PubMed
206. Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A, Bergsagel PL, Carpten J, Fonseca R. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia. 2010 Apr; 24 (4):833-42 Epub 2010 Mar 11
     View PubMed
207. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010 Feb 25; 115 (8):1594-604 Epub 2009 Dec 07
     View PubMed
208. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18; 115 (7):1343-50 Epub 2009 Dec 11
     View PubMed
209. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan; 11 (1):29-37 Epub 2009 Oct 21
     View PubMed
210. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H, International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009 Dec; 23 (12):2210-21 Epub 2009 Oct 01
     View PubMed
211. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009 Dec; 84 (12):1095-110
     View PubMed
212. Fonseca R. Plasma cell leukemia. Blood. 2009 Nov 20; 114(22):1575-6.
     
213. Gay F, Rajkumar SV, Jayabalan DS, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Chen-Kiang S, Roy V, Coleman M, Hayman SR, Buadi F, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (RD) as initial therapy for newly diagnosed multiple myeloma. Blood. 2009 Nov; 114(22):1119-20.
     
214. Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Hentz J, Pirooz N, Piza J, Zepeda VJJ, Fonseca R, Bergsagel PL, Leis J, Tiedemann RE, Stewart AK. A phase II trial comparison of once versus twice weekly bortezomib in CYBORD chemotherapy for newly diagnosed myeloma: identical high response rates and less toxicity. Blood. 2009 Nov 20; 114(22):255.
     
215. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar S, Reeder CB, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Thompson MA, Fonseca R, Stewart AK, Bergsagel PL, Mikhael JR, Roy V, Kyle R, Lacy MQ. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients. Blood. 2009 Nov 20; 114(22):1482-3.
     
216. Gay F, Hayman S, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel L, Dingli D, Reeder CB, Lust JA, Russel S, Roj V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle R, Greipp PR, Stewart AK, Rajkumar SV. Superiority of lenalidomide-dexamethasone versus thalidomide-dexamethasone as initial therapy for newly diagnosed multiple myeloma. Blood. 2009 Nov 20; 114(22):1494-5.
     
217. Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, Zeng S, Fonseca R, Kukreti V. Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. J Clin Oncol. 2009 Nov 20; 27(33):e194-7. Epub 2009 Oct 05.
     View PubMed
218. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20; 27 (30):5008-14 Epub 2009 Aug 31
     View PubMed
219. Ching WJ, Fonseca R. Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen. 2009 Oct; 50(8 Special Issue SI):697-707.
     
220. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114 (3):518-21 Epub 2009 Mar 26
     View PubMed
221. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009 Jul; 23(7):1337-41. Epub 2009 Feb 19.
     View PubMed
222. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009 Apr 15; 69 (8):3579-88 Epub 2009 Apr 07
     View PubMed
223. Conte G, Braggio E, Figueroa G, Fonseca R. Genetic markers as prognostic factors in multiple myeloma [Spanish]. Rev Med Chil. 2009 Apr; 137(4):552-8.
     
224. Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. High-resolution genomic analysis in Waldenstrom's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma. 2009 Mar; 9 (1):39-42
     View PubMed
225. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009 Mar; 94 (3):380-6 Epub 2009 Feb 11
     View PubMed
226. Chng WJ, Remstein ED, Fonseca R, Bergsagel PL, Vrana JA, Kurtin PJ, Dogan A. Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. Blood. 2009 Jan 15; 113 (3):635-45 Epub 2008 Oct 30
     View PubMed
227. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Kumar S, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol. 2008 Nov; 83 (11):840-1
     View PubMed
228. Bashey A, Perez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008 Oct; 14 (10):1118-1124
     View PubMed
229. Fonseca R, Rajkumar SV. Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial. Clin Lymphoma Myeloma. 2008 Oct; 8 (5):315-7
     View PubMed
230. Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, Ketterling RP, Knudson RA, Mulvihill EM, Tschumper RC, Wu X, Zeldenrust SR, Jelinek DF. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood. 2008 Sep 1; 112 (5):1931-41 Epub 2008 June 20
     View PubMed
231. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008 Jul 1; 26(19):3196-203. Epub 2008 May 12.
     View PubMed
232. Inwards DJ, Fishkin PA, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, Fonseca R, Morton RF, Veeder MH, Witzig TE. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008 Jul 1; 113 (1):108-16
     View PubMed
233. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008 May; 22 (5):1044-52 Epub 2008 Jan 24
     View PubMed
234. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest. 2008 May; 118 (5):1750-64
     View PubMed
235. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008 Apr 15; 111(8):4039-47. Epub 2008 Feb 11
     View PubMed
236. Ahmann GJ, Chng WJ, Henderson KJ, Price-Troska TL, DeGoey RW, Timm MM, Dispenzieri A, Greipp PR, Sable-Hunt A, Bergsagel L, Fonseca R. Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):666-73.
     View PubMed
237. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood. 2008 Feb 1; 111 (3):1603-9 Epub 2007 Nov 15
     View PubMed
238. Kelly SV, Burke RF, Lee KS, Torloni AS, Lee RW, Northfelt D, Fonseca R. Acute myocardial infarction: an unusual presentation of essential thrombocytosis in a 17-year-old man. Clin Adv Hematol Oncol. 2008 Feb; 6(2):133-6.
     View PubMed
239. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008 Feb; 13 (2):167-80
     View PubMed
240. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ 3rd, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008 Jan 15; 111 (2):785-9 Epub 2007 Oct 17
     View PubMed
241. Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007 Dec; 21 (6):1115-40, ix
     View PubMed
242. Curtis KK, Pruthi RK, Fonseca R, Gornet MK. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer. Urology. 2007 Oct; 70(4):811.e5-8.
     View PubMed
243. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007 Oct; 82 (10):1179-84
     View PubMed
244. Fonseca R, Hayman S. Waldenstrom macroglobulinaemia. Br J Haematol. 2007 Sep; 138(6):700-20. Epub 2007 Aug 02.
     View PubMed
245. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007 Sep; 21 (9):2035-42 Epub 2007 June 21
     View PubMed
246. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007 Aug; 12 (2):131-44
     View PubMed
247. Henry T, Fonseca R. Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia. Curr Opin Hematol. 2007 Jul; 14(4):369-74.
     View PubMed
248. Stewart AK, Fonseca R. Review of molecular diagnostics in multiple myeloma. Expert Rev Mol Diagn. 2007 Jul; 7(4):453-9.
     View PubMed
249. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21; 356 (25):2582-90
     View PubMed
250. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67 (8):3777-84
     View PubMed
251. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007 Apr 1; 67(7):2982-9.
     View PubMed
252. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
     View PubMed
253. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82: (3)323-41.
     View PubMed
254. Fonseca R, Stewart AK. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther. 2007 Mar; 6 (3):802-10
     View PubMed
255. Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007 Feb 1; 109 (3):1228-32 Epub 2006 July 13
     View PubMed
256. Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program. 2007; 304-10.
     View PubMed
257. Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, Garcia-Sanz R, Moro MJ, Aguilera C, Hernandez J, Xu R, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalez-Paz N, Gertz MA, San Miguel JF, Fonseca R. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007 Jan; 136(1):80-6.
     View PubMed
258. Chng WJ, Ketterling RP, Fonseca R. Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes Cancer. 2006 Dec; 45(12):1111-20.
     View PubMed
259. Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006 Nov; 20(11):2034-40. Epub 2006 Oct 05.
     View PubMed
260. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006 Oct 15; 108 (8):2755-63 Epub 2006 June 27
     View PubMed
261. Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR, Kyle RA, Dispenzieri A, Lacy MQ, Rajkumar SV, Gertz MA, Fonseca R. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006 Sep; 169 (2):150-3
     View PubMed
262. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81 (8):1047-53
     View PubMed
263. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006 May; 20(5):807-13.
     View PubMed
264. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood. 2006 May 1; 107 (9):3669-75 Epub 2005 Dec 22
     View PubMed
265. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006 Apr; 133 (2):158-64
     View PubMed
266. Halligan CS, Lacy MQ, Vincent Rajkumar S, Dispenzieri A, Witzig TE, Lust JA, Fonseca R, Gertz MA, Kyle RA, Pruthi RK. Natural history of thromboembolism in AL amyloidosis. Amyloid. 2006 Mar; 13(1):31-6.
     View PubMed
267. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica. 2006 Mar; 91(3):390-3. Epub 2006 Feb 17.
     View PubMed
268. Chng WJ, Winkler JM, Greipp PR, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Ahmann GJ, Henderson K, Blood E, Oken MM, Hulbert A, Van Wier SA, Santana-Davila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R. Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res. 2006 Mar; 30(3):266-71. Epub 2005 Aug 18.
     View PubMed
269. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20; 24(3):431-6. Epub 2005 Dec 19.
     View PubMed
270. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV, Kimlinger T, Lust JA, Fonseca R, Allred J, Witzig TE. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma. 2006 Jan; 47 (1):39-42
     View PubMed
271. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15; 106 (13):4050-3 Epub 2005 Aug 23
     View PubMed
272. Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica. 2005 Dec; 90: (12)1650-4.
     View PubMed
273. Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S, Paternoster S, Adeyinka A, Ketterling R, Van Dyke DL, Fonseca R, Kyle R. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005 Nov 15; 106 (10):3553-8 Epub 2005 July 19
     View PubMed
274. Chng WJ, Fonseca R. Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics. Clin Lymphoma Myeloma. 2005 Nov; 6 (3):200-7
     View PubMed
275. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, Van Wier SA, Ahmann GJ, Fonseca R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005 Oct 15; 106 (8):2837-40 Epub 2005 June 23
     View PubMed
276. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Oken MM, Blood E, Henderson K, Santana-Davila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005 Sep 15; 106 (6):2156-61 Epub 2005 May 26
     View PubMed
277. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005 Sep 10; 23(26):6339-44.
     View PubMed
278. Chng WJ, Fonseca R. Genomics in multiple myeloma: biology and clinical implications. Pharmacogenomics. 2005 Sep; 6(6):563-73.
     View PubMed
279. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. Journal of Clinical Oncology. 2005 Aug 20; 23(24):5668-74.
     View PubMed
280. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005 Aug 10; 23 (23):5347-56 Epub 2005 June 27
     View PubMed
281. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C, Glass J, Munker R. Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005 Apr; 78(4):288-94.
     View PubMed
282. Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL, Paz NG, Gertz MA, Fonseca R. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood. 2005 Jan 15; 105 (2):794-803 Epub 2004 Sept 23
     View PubMed
283. Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia. 2005 Jan; 19: (1)118-25.
     View PubMed
284. Higgins MJ, Fonseca R. Genetics of multiple myeloma. Baillieres Best Pract Res Clin Haematol 2005; 18(4):525-36.
     View PubMed
285. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R, Billadeau DD. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell. 2005 Jan; 7 (1):39-49
     View PubMed
286. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA, Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 1; 101 (11):2593-8
     View PubMed
287. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15; 22 (18):3751-7
     View PubMed
288. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004 Sep 15; 104 (6):1881-7 Epub 2004 Mar 25
     View PubMed
289. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004 Sep; 34(6):485-90.
     View PubMed
290. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004 Aug; 34(3):235-9.
     View PubMed
291. Abraham RS, Geyer SM, Ramirez-Alvarado M, Price-Troska TL, Gertz MA, Fonseca R. Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL). J Clin Immunol. 2004 Jul; 24 (4):340-53
     View PubMed
292. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood. 2004 Jul 1; 104 (1):40-2 Epub 2004 Mar 09
     View PubMed
293. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004 Jul; 79 (7):867-74
     View PubMed
294. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004 Jul; 34(2):161-7.
     View PubMed
295. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004 May 15; 103 (10):3960-3 Epub 2004 Jan 22
     View PubMed
296. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May 1; 103(9):3271-7. Epub 2004 Jan 15.
     View PubMed
297. Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia. 2004 Mar; 18(3):624-7.
     View PubMed
298. Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KC. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 1; 103(5):1799-806.
     View PubMed
299. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004 Feb 15; 64 (4):1546-58
     View PubMed
300. Ghobrial IM, Wolf RC, Pereira DL, Fonseca R, White WL, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Micallef IN, Porrata LF, Witzig TE. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc. 2004 Feb; 79(2):169-75.
     View PubMed
301. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, Lust JA, Greipp PR, Kyle RA, Gertz MA. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003 Dec; 10 (4):257-61
     View PubMed
302. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003 Nov; 4 (11):679-85
     View PubMed
303. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003 Oct; 17(10):2025-31.
     View PubMed
304. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Davila R, Gonzalez-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003 Oct 1; 102 (7):2562-7 Epub 2003 June 12
     View PubMed
305. Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol. 2003 Oct; 123 (2):305-8
     View PubMed
306. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003 Jun 1; 101(11):4569-75.
     View PubMed
307. Kyle RA, Child JA, Anderson K, Barlogie B, Bataille R, Bensinger W, Blade J, Boccadoro M, Dalton W, Dimopoulos M, Djulbegovic B, Drayson M, Durie B, Facon T, Fonseca R, Gahrton G, Greipp P, Harousseau JL, Harrington D, Hussein M, Joshua D, Ludwig H, Morgan G, Oken M, Powles R, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun; 121(5):749-57.
     View PubMed
308. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003 May 15; 101 (10):3801-8 Epub 2002 Dec 19
     View PubMed
309. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003 Apr; 17(4):775-9.
     View PubMed
310. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, Miguel JFS, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):110-5.
     View PubMed
311. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA. POEMS syndrome: definitions and long-term outcome. Blood. 2003 Apr 1; 101 (7):2496-506 Epub 2002 Nov 27
     View PubMed
312. Schop RFJ, Fonseca R. Genetics and cytogenetics of Waidenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):142-5.
     View PubMed
313. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003 Mar 1; 101 (5):1715-7 Epub 2002 Oct 17
     View PubMed
314. Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Rajkumar SV. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood. 2003 Feb 1; 101 (3):827-30 Epub 2002 Sept 05
     View PubMed
315. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003 Feb; 17 (2):427-36
     View PubMed
316. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003 Jan; 78 (1):21-33
     View PubMed
317. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003 Jan; 78(1):34-9.
     View PubMed
318. Fonseca R, Ahmann GJ. Assays for neoplastic cell enrichment in bone marrow samples. Methods Mol Med. 2003; 85:333-42.
     View PubMed
319. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol. 2002 Dec; 119 (3):665-71
     View PubMed
320. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002 Nov 1; 20: (21)4319-23.
     View PubMed
321. Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, Jalal SM, Qi Y, Kyle RA, Greipp PR, Fonseca R. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002 Oct 15; 100 (8):2996-3001
     View PubMed
322. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002 Aug 15; 100 (4):1417-24
     View PubMed
323. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002 Jul; 8(7):2210-6.
     View PubMed
324. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002 May 15; 99 (10):3735-41
     View PubMed
325. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res. 2002 Feb 1; 62(3):715-20.
     View PubMed
326. Schop RF, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Kyle RA, Greipp PR, Rajkumar SV, Gertz MA, Lust JA, Lacy MQ, Dispenzieri A, Witzig TE, Fonseca R. Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet. 2002 Jan 1; 132 (1):55-60
     View PubMed
327. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Therneau TM, Kyle RA, Greipp PR, Gertz MA. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001 Dec; 68 (4):269-75
     View PubMed
328. Rajkumar SV, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med. 2001 Nov 12; 161(20):2502-3.
     View PubMed
329. Hayman SR, Bailey RJ, Jalal SM, Ahmann GJ, Dispenzieri A, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Rajkumar SV, Witzig TE, Lust JA, Fonseca R. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001 Oct 1; 98 (7):2266-8
     View PubMed
330. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001 Aug; 15 (8):1274-6
     View PubMed
331. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Gertz MA. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001 Jul 15; 19: (14)3350-6.
     View PubMed
332. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001 Jun; 15 (6):981-6
     View PubMed
333. Fonseca R, Conte G, Greipp PR. Laboratory correlates in multiple myeloma: how useful for prognosis? Blood Rev. 2001 Jun; 15(2):97-102.
     View PubMed
334. Hayman SR, Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol. 2001 Jun; 2 (3):205-16
     View PubMed
335. Jalal SM, Law ME, Stamberg J, Fonseca R, Seely JR, Myers WH, Hanson CA. Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. Br J Haematol. 2001 Mar; 112 (4):975-80
     View PubMed
336. Teh SH, Farley DR, Gharib H, Fonseca R, Goellner JR, van Heerden JA. Primary thyroid amyloidosis and thyroid lymphoma. Contemp Surg. 2001 Mar; 57(3):137-9.
     
337. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001 Jan; 76 (1):22-8
     View PubMed
338. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Larson D, Therneau TM, Kyle RA, Litzow MR, Greipp PR, Gertz MA. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant. 2000 Nov; 26(9):979-83.
     View PubMed
339. Fonseca R, Rajkumar SV, Ahmann GJ, Jalal SM, Hoyer JD, Gertz MA, Kyle RA, Greipp PR, Dewald GW. Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis. Leuk Lymphoma. 2000 Oct; 39 (3-4):391-5
     View PubMed
340. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000 Sep; 75(9):897-901.
     View PubMed
341. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000 Aug; 6 (8):3111-6
     View PubMed
342. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol. 2000 Jun; 113(6):831-7.
     View PubMed
343. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000 Apr; 109(1):24-9.
     View PubMed
344. Shoho AR, Porrata LF, Fonseca R. 76-year-old man with retroperitoneal bleeding after prostatectomy. Mayo Clin Proc. 2000 Mar; 75(3):299-302.
     View PubMed
345. Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE, Egan KS, Martenson JA, Burgart LJ, Inwards DJ. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000 Jan 1; 88 (1):154-61
     View PubMed
346. Gertz MA, Fonseca R, Rajkumar SV. Waldenstrom's macroglobulinemia. Oncologist. 2000; 5 (1):63-7
     View PubMed
347. Fonseca R, Greipp PR. Multiple myeloma. Conn's Current Therapy. 2000; 466-9.
     
348. Fonseca R, Coignet LJ, Dewald GW. Cytogenetic abnormalities in multiple myeloma. Hematol Oncol Clin North Am. 1999 Dec; 13 (6):1169-80, viii
     View PubMed
349. Fonseca R, Hoyer JD, Aguayo P, Jalal SM, Ahmann GJ, Rajkumar SV, Witzig TE, Lacy MQ, Dispenzieri A, Gertz MA, Kyle RA, Greipp PR. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk Lymphoma. 1999 Nov; 35 (5-6):599-605
     View PubMed
350. Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999 Sep; 24(5):497-503.
     View PubMed
351. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, Greipp PR, Gertz MA. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999 Aug; 113 (1):73-7
     View PubMed
352. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Beta(2)-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999 Jun; 23(12):1261-1266.
     View PubMed
353. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999 Jun; 23(12):1267-72.
     View PubMed
354. Fonseca R, O'Neill BP, Foote RL, Grill JP, Sloan JA, Frytak S. Cerebral toxicity in patients treated for small cell carcinoma of the lung. Mayo Clin Proc. 1999 May; 74 (5):461-5
     View PubMed
355. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, Litzow MR, Gertz MA, Greipp PR. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999 May; 17: (5)1551-7.
     View PubMed
356. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999 Mar; 13 (3):469-72
     View PubMed
357. Fonseca R, Ahmann GJ, Jalal SM, Dewald GW, Larson DR, Therneau TM, Gertz MA, Kyle RA, Greipp PR. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 1998 Dec; 103 (3):704-10
     View PubMed
358. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol. 1998 Nov; 59 (3):230-3
     View PubMed
359. Fonseca R, Yamakawa M, Nakamura S, van Heerde P, Miettinen M, Shek TW, Myhre Jensen O, Rousselet MC, Tefferi A. Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol. 1998 Oct; 59 (2):161-7
     View PubMed
360. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998 Jul; 16 (7):2377-81
     View PubMed
361. Fonseca R, Witzig TE, Olson LJ, Edwards BS, Khoor A, Walker RC. Disseminated Kaposi's sarcoma after heart transplantation: association with Kaposi's sarcoma-associated herpesvirus. J Heart Lung Transplant. 1998 Jul; 17 (7):732-6
     View PubMed
362. Fonseca R, Witzig TE, Gertz MA, Kyle RA, Hoyer JD, Jalal SM, Greipp PR. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol. 1998 May; 101 (2):296-301
     View PubMed
363. Fonseca R, Hartmann LC, Petersen IA, Donohue JH, Crotty TB, Gisvold JJ. Ductal carcinoma in situ of the breast. Ann Intern Med. 1997 Dec 1; 127 (11):1013-22
     View PubMed
364. Fonseca R, Tefferi A, Strickler JG. Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report. Am J Hematol. 1997 Jul; 55 (3):148-55
     View PubMed
365. Fonseca R, Frytak S, Mokri B. The case of the phantom bladder. J Urol. 1997 Apr; 157(4):1354.
     View PubMed
366. Fonseca R, Tefferi A. Practical aspects in the diagnosis and management of aplastic anemia. Am J Med Sci. 1997 Mar; 313 (3):159-69
     View PubMed